European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2023 update
M Rouprêt, T Seisen, AJ Birtle, O Capoun… - European urology, 2023 - Elsevier
Abstract Context The European Association of Urology (EAU) guidelines panel on upper
urinary tract urothelial carcinoma (UTUC) has updated the guidelines to aid clinicians in …
urinary tract urothelial carcinoma (UTUC) has updated the guidelines to aid clinicians in …
Bladder cancer
L Dyrskjøt, DE Hansel, JA Efstathiou… - Nature Reviews …, 2023 - nature.com
Bladder cancer is a global health issue with sex differences in incidence and prognosis.
Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways …
Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways …
[HTML][HTML] Nivolumab plus gemcitabine–cisplatin in advanced urothelial carcinoma
MS Van Der Heijden, G Sonpavde… - … England Journal of …, 2023 - Mass Medical Soc
Background No new agent has improved overall survival in patients with unresectable or
metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy …
metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy …
Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer
T Powles, BP Valderrama, S Gupta… - … England Journal of …, 2024 - Mass Medical Soc
Background No treatment has surpassed platinum-based chemotherapy in improving
overall survival in patients with previously untreated locally advanced or metastatic …
overall survival in patients with previously untreated locally advanced or metastatic …
Cuproptosis induced by ROS responsive nanoparticles with elesclomol and copper combined with αPD‐L1 for enhanced cancer immunotherapy
B Guo, F Yang, L Zhang, Q Zhao, W Wang… - Advanced …, 2023 - Wiley Online Library
Cuproptosis is a new cell death that depends on copper (Cu) ionophores to transport Cu into
cancer cells, which induces cell death. However, existing Cu ionophores are small …
cancer cells, which induces cell death. However, existing Cu ionophores are small …
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
T Powles, J Bellmunt, E Comperat… - Annals of …, 2022 - annalsofoncology.org
Urothelial carcinoma (UC), also described as bladder cancer, is the 10th most common
cancer type worldwide, with an estimated 549 000 new cases and 200 000 deaths in 2018 …
cancer type worldwide, with an estimated 549 000 new cases and 200 000 deaths in 2018 …
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised …
T Powles, T Csőszi, M Özgüroğlu, N Matsubara… - The Lancet …, 2021 - thelancet.com
Summary Background PD-1 and PD-L1 inhibitors are active in metastatic urothelial
carcinoma, but positive randomised data supporting their use as a first-line treatment are …
carcinoma, but positive randomised data supporting their use as a first-line treatment are …
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
M Santoni, A Rizzo, J Kucharz, V Mollica… - Cancer Immunology …, 2023 - Springer
Background Immunotherapy has determined unprecedented long-term responses in several
hematological and solid tumors. In the MOUSEION-03 study, we conducted a meta-analysis …
hematological and solid tumors. In the MOUSEION-03 study, we conducted a meta-analysis …
Treatment of muscle‐invasive and advanced bladder cancer in 2020
VG Patel, WK Oh, MD Galsky - CA: a cancer journal for …, 2020 - Wiley Online Library
Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades,
the systemic management of muscle‐invasive and advanced bladder cancer has primarily …
the systemic management of muscle‐invasive and advanced bladder cancer has primarily …